BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics

…, G Basi, MJ Bienkowski, DG Branstetter… - Human molecular …, 2001 - academic.oup.com
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by accumulation of
amyloid plaques and neurofibrillary tangles in the brain. The major components of plaque, β…

Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone

DG Branstetter, SD Nelson, JC Manivel, JY Blay… - Clinical Cancer …, 2012 - AACR
Purpose: Giant-cell tumor of bone (GCTB) is a locally aggressive, benign osteolytic tumor in
which bone destruction is mediated by RANK ligand (RANKL). The RANKL inhibitor …

[HTML][HTML] Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule*♦

…, MF Wolfson, RA Sorensen, DG Branstetter… - Journal of Biological …, 2005 - ASBMB
Dendritic cells (DCs) are a phenotypically and functionally heterogenous population of
leukocytes with distinct subsets serving a different set of specialized immune functions. Here we …

[PDF][PDF] Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity

…, T Dang, JW O'Neill, R Mallari, X Zhao, DG Branstetter… - Cancer cell, 2014 - cell.com
Death receptor agonist therapies have exhibited limited clinical benefit to date. Investigations
into why Apo2L/TRAIL and AMG 655 preclinical data were not predictive of clinical …

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

…, SJ Zoog, Y Pan, J Wall, DG Branstetter… - Cancer biology & …, 2010 - Taylor & Francis
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to death receptors 4
and 5 (DR4, DR5) to transduce apoptotic signals. Conatumumab (AMG 655) is an …

[HTML][HTML] Osteoclast differentiation is impaired in the absence of inhibitor of κB kinase α

ML Chaisson, DG Branstetter, JM Derry… - Journal of Biological …, 2004 - ASBMB
Signaling through the receptor activator of nuclear factor κB (RANK) is required for both
osteoclast differentiation and mammary gland development, yet the extent to which RANK …

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive …

J Canon, R Bryant, M Roudier, DG Branstetter… - Breast cancer research …, 2012 - Springer
Tumor cells in bone can induce the activation of osteoclasts, which mediate bone resorption
and release of growth factors and calcium from the bone matrix, resulting in a cycle of tumor …

Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells

MS Lippa, LD Strockbine, TT Le, DG Branstetter… - Apoptosis, 2007 - Springer
Tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) selectively induces
apoptosis in transformed cells. Normal cells and certain tumor cells can evade Apo2L/TRAIL …

Tg. AC genetically altered mouse: assay working group overview of available data

…, RW Tennant, RE Stoll, DG Branstetter… - Toxicologic …, 2001 - journals.sagepub.com
In a Government/Industry/Academic partnership to evaluate alternative approaches to
carcinogenicity testing, 21 pharmaceutical agents representing a variety of chemical and …

A comparison of the lung adenoma response in strain A/J mice after intraperitoneal and oral administration of carcinogens

…, TR Loeb, JE Klaunig, DG Branstetter - Toxicology and applied …, 1984 - Elsevier
This study was undertaken to compare the ability of a series of compounds from different
chemical classes to induce lung tumors in strain A/J mice after either ip or po administration. 3-…